403 related articles for article (PubMed ID: 24604058)
1. Microenvironmental clues for glioma immunotherapy.
Platten M; Ochs K; Lemke D; Opitz C; Wick W
Curr Neurol Neurosci Rep; 2014 Apr; 14(4):440. PubMed ID: 24604058
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
[TBL] [Abstract][Full Text] [Related]
3. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
Weller M; Fontana A
Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
[TBL] [Abstract][Full Text] [Related]
4. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.
Yang L; Ng KY; Lillehei KO
Cancer Control; 2003; 10(2):138-47. PubMed ID: 12712008
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of the glioma microenvironment].
Herrlinger U; Platten M
Nervenarzt; 2015 Jun; 86(6):684, 686-8, 690-1. PubMed ID: 25962344
[TBL] [Abstract][Full Text] [Related]
7. [Brain tumor immunotherapy: Illusion or hope?].
Migliorini D; Dutoit V; Walker PR; Dietrich PY
Bull Cancer; 2017 May; 104(5):476-484. PubMed ID: 28318492
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models.
Alghamri MS; Núñez FJ; Kamran N; Carney S; Altshuler D; Lowenstein PR; Castro MG
Methods Enzymol; 2020; 631():91-106. PubMed ID: 31948569
[TBL] [Abstract][Full Text] [Related]
9. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
10. CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.
Murphy KA; Erickson JR; Johnson CS; Seiler CE; Bedi J; Hu P; Pluhar GE; Epstein AL; Ohlfest JR
J Immunol; 2014 Jan; 192(1):224-33. PubMed ID: 24293627
[TBL] [Abstract][Full Text] [Related]
11. Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme.
Sokratous G; Polyzoidis S; Ashkan K
Hum Vaccin Immunother; 2017 Nov; 13(11):2575-2582. PubMed ID: 28362548
[TBL] [Abstract][Full Text] [Related]
12. Current state and future prospects of immunotherapy for glioma.
Kamran N; Alghamri MS; Nunez FJ; Shah D; Asad AS; Candolfi M; Altshuler D; Lowenstein PR; Castro MG
Immunotherapy; 2018 Feb; 10(4):317-339. PubMed ID: 29421984
[TBL] [Abstract][Full Text] [Related]
13. Vaccine-based immunotherapeutic approaches to gliomas and beyond.
Weller M; Roth P; Preusser M; Wick W; Reardon DA; Platten M; Sampson JH
Nat Rev Neurol; 2017 Jun; 13(6):363-374. PubMed ID: 28497804
[TBL] [Abstract][Full Text] [Related]
14. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
15. Dendritic-cell- and peptide-based vaccination strategies for glioma.
Yamanaka R
Neurosurg Rev; 2009 Jul; 32(3):265-73; discussion 273. PubMed ID: 19214609
[TBL] [Abstract][Full Text] [Related]
16. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.
Mishchenko TA; Turubanova VD; Gorshkova EN; Krysko O; Vedunova MV; Krysko DV
Front Immunol; 2023; 14():1299064. PubMed ID: 38274827
[TBL] [Abstract][Full Text] [Related]
17. Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
Najem H; Khasraw M; Heimberger AB
Cells; 2021 Aug; 10(8):. PubMed ID: 34440802
[TBL] [Abstract][Full Text] [Related]
18. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
19. Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.
Wang JY; Bettegowda C
J Neurooncol; 2015 Jul; 123(3):373-83. PubMed ID: 25697584
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
